<DOC>
	<DOCNO>NCT00107211</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide person 's white blood cell may help body build effective immune response kill tumor cell . Injecting vaccine directly lymph node may cause strong immune response kill tumor cell . Giving vaccine therapy surgery may effective treatment ductal carcinoma situ breast . PURPOSE : This phase I trial study side effect best way give vaccine therapy treat patient undergo surgery ductal carcinoma situ breast .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients Who Are Undergoing Surgery Ductal Carcinoma In Situ Breast</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility safety neoadjuvant ultrasound-guided intranodal vaccine therapy comprise autologous dendritic cell pulse recombinant HER2/neu peptides patient ductal carcinoma situ breast . - Determine sensitization CD4+ CD8+ T cell HER2/neu patient treat vaccine . - Determine clinical response patient treat vaccine . Secondary - Correlate post-vaccine sensitization CD4+ CD8+ T cell HER2/neu clinical response patient treat vaccine . OUTLINE : This pilot study . Patients undergo leukapheresis 2-3 hour obtain lymphocyte monocyte . Monocytes culture sargramostim ( GM-CSF ) , interleukin-4 , interferon gamma , lipopolysaccharides production dendritic cell ( DC ) . DC pulse recombinant HER2/neu peptide produce dendritic cell vaccine . Approximately 2 day leukapheresis , patient receive vaccine intranodally ( 2 different lymph node ) ultrasound guidance week 4 week absence unacceptable toxicity . Patients undergo second leukapheresis obtain T lymphocytes immunologic analysis . Within 2-3 week completion vaccine therapy , patient undergo lumpectomy mastectomy AND sentinel lymph node biopsy . After completion study treatment , patient follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal carcinoma situ ( DCIS ) breast OR DCIS microinvasion ( &lt; 1 mm ) core biopsy excisional biopsy HER2/neu positive tumor , define &gt; 10 % tumor population express HER2/neu immunohistochemical stain No evidence invasive disease MRI ( perform within past month ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Over 18 Sex Not specify Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic No thrombocytopenia ( i.e. , platelet count &lt; 75,000/mm^3 ) No coagulopathy Hepatic No hepatitis C positivity INR &gt; 1.5 PTT &gt; 50 sec Renal Not specify Cardiovascular Ejection fraction â‰¥ 50 % MUGA echocardiogram No major cardiac illness Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity No toxicity &gt; grade 1 No preexist medical illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy No prior ipsilateral breast axillary radiotherapy Surgery No prior ipsilateral axillary dissection No prior complete excisional biopsy DCIS Other No prior definitive treatment DCIS No concurrent medication would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>